Glanbia shares jump 11% as guidance raised on strong H1 growth in H&N, Dairy

Glanbia (IR:GL9) shares surged over 11% after the company raised its full-year adjusted earnings per share guidance to 130-133 $cent, citing robust performance in its Health & Nutrition (sales up 18%) and Dairy Nutrition (sales up 14.1%) segments in the first half of 2025. Despite a 6% increase in overall revenue to $1.93 billion, group EBITDA before exceptional items declined 7.5% and profit after tax fell, largely due to a 3.8% revenue drop in Performance Nutrition. However, the company also increased its interim dividend by 10% and executed share buybacks, signaling confidence in its outlook despite mixed profitability metrics.

Analysis

Glanbia's shares surged over 11% following an upward revision of its full-year adjusted earnings guidance to a range of 130 to 133 $cent per share, a move prompted by strong first-half performance in key divisions. The company's Health & Nutrition segment saw sales grow 18%, driven by a mix of organic volume and acquisitions, while the Dairy Nutrition division's revenue increased 14.1% on higher volumes and prices. Despite this top-line strength, which pushed total group revenue up 6% to $1.93 billion, significant challenges remain. The largest segment, Performance Nutrition, experienced a 3.8% revenue decline due to a 3.5% drop in volumes. This divisional weakness was a key factor in the overall decline in profitability, with group EBITDA falling 7.5% and margins contracting notably to 12.5% from 14.4% a year prior. Furthermore, basic earnings per share fell 28.6%. In a signal of confidence, management increased the interim dividend by 10% and continued its share buyback program, while also actively reshaping its portfolio through the acquisition of Sweetmix and the divestiture of its Body & Fit e-commerce unit.

Key Decisions for Investors

• Investors should weigh the upgraded full-year EPS guidance and 10% dividend hike, which signal management's confidence, against the risk that the stock's 11% rally may have already priced in this optimism.
• Closely monitor the turnaround in the Performance Nutrition segment, as its 3.8% revenue decline is the primary source of pressure on group profitability and a key risk to achieving the newly raised guidance.
• Evaluate the impact of the ongoing portfolio restructuring, including the Sweetmix acquisition and Body & Fit divestiture, on the company's future growth profile and its ability to improve consolidated margins.